Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Risperidone effectiveness is measured by time to relapse within the 52 week period.
Effectiveness of the drug is assessed by the Clinical Global Impression Scale and Positive and Negative Syndrome Scale; safety as assessed by the Extrapyramidal Symptom Rating Scale and treatment-emergent adverse events during the 52 week period.
18 Years to 70 Years (Adult, Senior)
February 28, 2006
May 18, 2011
† Study has passed its completion date and status has not been verified in more than two years.